FDA Watch: Another First as Agency Approves NGS Oncology Companion Dx for Multiple Therapies

Email not displaying correctly? View it in your browser.

Aug 15, 2017

NEWS
FDA Watch: Another First as Agency Approves NGS Oncology Companion Dx for Multiple Therapies
From - Laboratory Industry Report
The FDA made a stir in May by approving a cancer drug (Keytruda (pembrolizumab) PD-1/PD-L1 inhibitor from Merck) administered on the basis of a…
Read More

EMERGING TESTS
Sequencing-Based Screening Needed for Therapeutic Stem Cells
From - Diagnostic Testing & Emerging Technologies
One of the potential therapeutic advantages of stem cells is that they can regenerate. But, a new study, published May 11 in Nature, suggests that the longer…
Read More

CASE OF THE MONTH
Theranos and Walgreens Bury the Hatchet—For Now
From - G2 Compliance Advisor
It all looked so promising back in 2015. Privately-held Theranos was poised to usher in a new era of diagnostics with its revolutionary fingerprick technology for…
Read More

EMPLOYMENT LAW
Employment Law Update for August 2017
From - G2 Blog
By Mike O'Brien bio
Here is my periodic update prepared for interested HR professionals trying to deal with the complex American employment laws…
Read More

For questions concerning delivery of this email, please contact customer service at:
(888) 729-2315 | customerservice@plainlanguagemedia.com

Unsubscribe | Forward to a Friend